Evidence map›Paper›PMID 42201640›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Targeting KDM3B Elicits Anti-tumor Immunity by Alleviating SHP1-mediated STING Suppression in Triple-Negative Breast Cancer.

Xiaolong Wang, Wenhao Li, Yifei Wang, Ning Zhang, Bing Chen, Wenjing Zhao, Lijuan Wang, Dan Luo, Qifeng Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaolong WangDepartment of Breast Surgery, General Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Wenhao LiDepartment of Breast Surgery, General Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Yifei WangDepartment of Breast Surgery, General Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Ning ZhangDepartment of Breast Surgery, General Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Bing ChenBiological Resource Center, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Wenjing ZhaoBiological Resource Center, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Lijuan WangBiological Resource Center, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Dan LuoBiological Resource Center, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Qifeng YangDepartment of Breast Surgery, General Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China.ORCID https://orcid.org/0000-0003-0576-8513

Funding

Shandong Provincial Natural Science Foundation ZR2024MH265Special Foundation for Taishan Scholars tstp20250509Special Support Plan for National High Level Talents (Ten Thousand Talents Program) W01020103
6 · The paper itself

Abstract

Immunotherapy has emerged as a promising therapeutic option for cancer management, but its applicability in patients with triple-negative breast cancer (TNBC) is limited by the low efficacy due to the immunosuppressive tumor microenvironment (TME). Here, we identify lysine demethylase 3B (KDM3B) as an essential mediator of immune evasion in TNBC. KDM3B expression is negatively correlated with cytotoxic T lymphocyte (CTL) infiltration. Genetic or pharmacologic inhibition of KDM3B facilitates the recruitment and activation of CD8

Indexed as

Jumonji Domain-Containing Histone DemethylasesMembrane ProteinsProtein Tyrosine Phosphatase, Non-Receptor Type 6Triple Negative Breast NeoplasmsAnimalscGAS-STING Signaling PathwayFemaleHumansMiceSTING ProteinTumor MicroenvironmentJumonji Domain-Containing Histone DemethylasesMembrane ProteinsProtein Tyrosine Phosphatase, Non-Receptor Type 6STING Proteinanti‐tumor immunityKDM3BSHP1STINGtriple–negative breast cancer

Identifiers

PMID42201640
PMCPMC13335874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.